NewAmsterdam Pharma Company N.V. (NAMSW) Total liabilities 2022–2025
NewAmsterdam Pharma Company N.V. (NAMSW) total liabilities at each fiscal year-end, per SEC filings.
$85.9MFY2025 · since FY2022: $48.4M → $85.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $85.9M | -19.9% |
| FY2024 | $107.1M | +82.5% |
| FY2023 | $58.7M | +21.2% |
| FY2022 | $48.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Shareholders’ equityNAMSW overview →